AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01844700
Drug: aripiprazole, quetiapine, or risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
Trial: NCT01817777
Drug: Metformin Small Pack
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
Trial: NCT01817777
Drug: Metformin Large Pack
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The large pack will consist of 1 month's supply of metformin.
Trial: NCT04053387
Drug: tapinarof cream, 1%
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score
Trial: NCT04250792
Drug: Naltrexone Pill
RxNorm normalized name: naltrexone Pill
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: role of low dose naltrexone in patients affected with psoriasis
Trial: NCT03680521
Drug: Sitravatinib
RxNorm normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitravatinib oral capsule administered daily for 6-8 weeks in segments 1 and 2.
Trial: NCT03680521
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks in segment 2.
Trial: NCT04398225
Drug: Centanafadine
RxNorm normalized name: Centanafadine
DrugBank: Centanafadine (DB14841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release capsule
Trial: NCT01718847
Drug: NOV120101 (Poziotinib)
RxNorm normalized name: Poziotinib
DrugBank: Poziotinib (DB12114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg PO once daily until disease progression or unacceptable toxicity development
Trial: NCT01950923
Drug: sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02428881
Drug: onabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter
Trial: NCT03760185
Drug: Brimonidine Tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subjects will apply brimonidine tartrate to one eye (right eye) only for the duration of study participation.
Trial: NCT02559856
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02559856
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002670
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02013648
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02013648
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02013648
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02013648
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00488345
Drug: Tygacil
RxNorm normalized name: Tygacil
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02248233
Drug: Nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Jiangsu Jichuan Pharmaceutical Co., Ltd., Jiangsu Province, China
Trial: NCT02248233
Drug: Saline + citicoline
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days.
Trial: NCT03113344
Drug: cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs
DrugBank: Carbapenem (DB18912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
Trial: NCT00489398
Drug: epinastine HCL and olopatadine HCL
RxNorm normalized name: Epinastine Hydrochloride
DrugBank: Epinastine (DB00751)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03218553
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone : first dose : 0,2mg.kg-1 at the end of the surgical procedure, second dose (0,2 mg.kg-1) 24 hours after the surgery
Trial: NCT00780910
Drug: MP-424
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 750 mg every 8 hours for 12 weeks
Trial: NCT00780910
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 - 1000 mg/day based on body weight for 24 weeks
Trial: NCT03277599
Drug: IV patient-controlled analgesia (PCA) tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
Trial: NCT03277599
Drug: ultrasound guided superficial cervical plexus block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine
Trial: NCT03277599
Drug: ultrasound guided Great Auricular nerve block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
Trial: NCT01842256
Drug: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)
Trial: NCT01842256
Drug: atorvastatin 40mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 1 Tablet (atorvastatin 40mg),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)
Trial: NCT03032484
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
Trial: NCT00141011
Drug: Ancrod (Viprinex)
RxNorm normalized name: ancrod
DrugBank: Ancrod (DB05099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours
Trial: NCT00780910
Drug: Peginterferon Alfa-2b
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 mcg/kg/week for 24 weeks
Trial: NCT04025957
Drug: SHR-1501
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT04103814
Drug: magnesium-cannabidiolic acid cream
RxNorm normalized name: Cannabidiolic acid
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive Mg-CBDa (magnesium-cannabidiolic acid) cream for topical treatment of hallux rigidus or hallux valgus.
Trial: NCT01928537
Drug: rigosertib sodium
RxNorm normalized name: Rigosertib
DrugBank: Rigosertib (DB12146)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00023595
Drug: Active Medication Alone
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication for coronary artery disease and heart failure management.
Trial: NCT01969409
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: i.v. rituximab given on two occasions 14 days apart.
Trial: NCT06172023
Drug: Silver Nanoparticles Irrigant
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nanosilver irrigant solution
Trial: NCT06172023
Drug: Chitosan Nanoparticles Irrigant
RxNorm normalized name: Chitosan
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan nanoparticles irrigant solution
Trial: NCT01495013
Drug: 1mg Glimepiride/10mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet by mouth once a day
Trial: NCT01495013
Drug: 2mg Glimepiride/10mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet by mouth once a day
Trial: NCT01495013
Drug: 3mg Glimepiride/10mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet by mouth once a day
Trial: NCT01495013
Drug: 4mg Glimepiride/10mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet by mouth once a day
Trial: NCT01495013
Drug: 1mg Glimepiride/20mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet by mouth once a day
Trial: NCT01495013
Drug: 2mg Glimepiride/20mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet by mouth once a day
Trial: NCT01495013
Drug: 3mg Glimepiride/20mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet by mouth once a day
Trial: NCT01495013
Drug: 4mg Glimepiride/20mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet by mouth once a day
Trial: NCT01495013
Drug: 1mg Glimepiride
RxNorm normalized name: glimepiride 1 MG
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
Trial: NCT01495013
Drug: 2mg Glimepiride
RxNorm normalized name: glimepiride 2 MG
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
Trial: NCT01495013
Drug: 3mg Glimepiride
RxNorm normalized name: glimepiride 3 MG
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
Trial: NCT01495013
Drug: 4mg Glimepiride
RxNorm normalized name: glimepiride 4 MG
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
Trial: NCT01495013
Drug: 10mg Atorvastatin
RxNorm normalized name: atorvastatin 10 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
Trial: NCT01495013
Drug: 20mg Atorvastatin
RxNorm normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
Trial: NCT00815633
Drug: Alefacept
RxNorm normalized name: Alefacept
DrugBank: Alefacept (DB00092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg intramuscular injection weekly for 12 weeks
Trial: NCT02978495
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 1,5 once a week, for 12 weeks
Trial: NCT02978495
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80mg/m2 weekly for 12 weeks
Trial: NCT00001854
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02908217
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
Trial: NCT01313533
Drug: Vein soak treated with Lactated Ringers Solution
RxNorm normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vein soak
Trial: NCT02259803
Drug: Telmisartan/amlodipine fixed-dose combination (FDC) tablet
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02259803
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02259803
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03538457
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are tested for their normal prescription paracetamol medication
Trial: NCT00855335
Drug: Darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.
Trial: NCT00855335
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg tablet twice daily up to 12 weeks postpartum.
Trial: NCT00855335
Drug: Etravirine
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200 mg (1\*200 mg/2\*100 mg) tablets twice daily up to 12 weeks postpartum.
Trial: NCT00855335
Drug: Rilpivirine
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One 25 mg tablet once daily up to 12 weeks postpartum.
Trial: NCT00855335
Drug: Darunavir/Cobicistat (FDC)
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
Trial: NCT01871922
Drug: Atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine
Trial: NCT01156350
Drug: Busulfan - Fludarabine - TBI
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This RICE NK protocol is a multicenter study of Haplo- HSCT using RIC with fludarabine (180 mg/m2), Busulfan IV (3,2 to 4,8 mg/kg/d), TBI 2 grays and CD3/CD19 graft depletion. A minimum of 8 106 CD34+ cells/kg were infused on day 0. No post grafting immunosuppression was applied if the graft contained \< 2.5 x 104 CD3+ cells/kg
Trial: NCT03163667
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral tablets
Trial: NCT00157261
Drug: tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00099905
Drug: vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01215331
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulins most commonly used during pregnancy by our group are rapid acting insulins and long acting human insulins (long acting analogs are not authorized in pregnancy). An ultra-fast acting insulin will be started before a meal (1, 2 or 3 meals) at 4-6 IU (according to the weight) if the glycemic value 2 hours after this meal is ≥ 6.7 mmol/L in 50% of cases. It will be increased by 2 units every 2 days until obtaining the aimed objectives. Long acting insulin will be started at 4-6 units at bedtime if the glycemic value before breakfast is ≥ 5.3 mmol/L in 50% of cases, and it will be increased by 2 units every 2 days until reaching the objective. A combination of both insulins could be necessary (maximum of 4 injections per day).
Trial: NCT01215331
Drug: Metformin, glyburide and insulin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (tablets of 500 mg) will be started at 250 mg/day x 1 day, and increased thereafter by 250 mg per day every 3 days until obtaining an adequate glycemic control. If metformin does not prove its effect at a dose of 750 mg, or if the side effects (mainly gastric) command to slow down or not to increase the posology, glyburide will be added.~Glyburide (tablets of 5 mg) will be started at a dose of 2.5 mg and will be increased by 2.5 mg every 3 days until obtaining an adequate glycemic control. The maximal dose in the study will bw 10 mg. It corresponds to the half of the maximal dose recommended in Canada.~Treatment failure is defined as glycemia above the Canadian Diabetes Association therapeutic objectives in spite of maximal doses or whether the doses can not be increased because of side effects. Insulin will be added to oral hypoglycemic agents.
Trial: NCT01257750
Drug: Pazopanib (5mg/ml)
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical pazopanib, 4 times per day for 3 weeks
Trial: NCT01758120
Drug: Prednisone alone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. prednisone alone: prednisone(0.5mg/kg/day\*6 months);~2. supportive care,including ACE-I or ARBs and blood pressure control
Trial: NCT00179686
Drug: CC-5013
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02871440
Drug: Omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02871440
Drug: Optive Advanced
RxNorm normalized name: Refresh Optive Advanced
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04647357
Drug: SHR-1316
RxNorm normalized name: Immunoglobulin G4 (52-glycine, 57-phenylalanine, 227-proline, 233-alanine, 234-alanine, 446-alanine), anti-(human programmed death-ligand 1) (human-mus musculus monoclonal SHR-1316 .gamma.4-chain) fusion protein with peptide linker ((ggggs)4g) fusion protein with 20-136-type II transforming growth factor .beta. receptor (human isoform 1), disulfide with (85-glutamic acid) human-mus musculus monoclonal SHR-1316 .kappa.-chain, dimer
DrugBank: Retlirafusp alfa (DB17517)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-L1 antibody，Maintenance therapy, The drug was administered every three weeks
Trial: NCT04481841
Drug: oryzanol + vitamin B2 (riboflavin) + vitamin E
RxNorm normalized name: VITAMIN B2
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.~2.Therapeutic regimen of experimental group On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment.
Trial: NCT00255502
Drug: metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03202303
Drug: Cannabidivarin
RxNorm normalized name: Cannabidivarin
DrugBank: Cannabidivarin (DB14050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing of 10 mg/kg/day of CBDV
Trial: NCT03815344
Drug: Standard
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 units diluted in 100mL of Normal Saline injected laparoscopic needle
Trial: NCT03815344
Drug: Standard-vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg
Trial: NCT02318433
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Data demonstrates that low doses of dexamethasone preserves chondrocyte viability, protects collagen, and maintains proteoglycan synthesis in cartilage subjected to injurious compression.
Trial: NCT02318433
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00020683
Drug: incyclinide
RxNorm normalized name: Incyclinide
DrugBank: Incyclinide (DB11647)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose given orally
Trial: NCT00020683
Drug: incyclinide
RxNorm normalized name: Incyclinide
DrugBank: Incyclinide (DB11647)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose given orally
Trial: NCT00319007
Drug: Inulin (probiotic)
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02115529
Drug: Nabilone
RxNorm normalized name: Nabilone
DrugBank: Nabilone (DB00486)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nabilone (0.5 mg) or placebo given preoperatively